Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET

Company Participants

Paul Little - CFO

David-Alexandre Gros - CEO

Steve Perrin - President and Chief Scientific Officer

Jeff Bornstein - Chief Medical Officer

Conference Call Participants

Thomas Smith - SVB Securities

Rami Katkhuda - LifeSci Capital

Operator

Greetings, and welcome to Eledon Pharmaceuticals Second Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded today, August 11, 2022.

I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Eledon. Please go ahead sir.

Paul Little

Good afternoon everyone and thank you for joining Eledon’s second quarter 2022 operating and financial results conference call. I am joined on today’s call by David-Alexandre Gros, Chief Executive Officer; and Jeff Bornstein, Chief Medical Officer. Steve Perrin, our President and Chief Scientific Officer will not join today’s call because he is attending a funeral. Earlier today, Eledon issued a press release announcing financial results for the second quarter ended June 30, 2022. You may access the release under the Investors tab on our company’s website at eledon.com.

I would like to remind everyone that statements made during this conference call relating to Eledon’s expected future performance, future business prospects for future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of Eledon. Eledon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to the risk factors set forth in Eledon’s reports filed with the U.S. Securities and Exchange Commission.

Now I would like to pass the call to Eledon’s CEO, Dr. David-Alexandre Gros, DA.

David-Alexandre Gros

Thank you, Paul, and thank you all for joining the call today. The second quarter marked the beginning of an exciting period for Eledon as we reported the first of four distinct clinical readouts from our tegoprubart pipeline with positive phase 2a results in ALS. This year, we have been focused on execution across a four clinical trials, kidney transplantation, ALS, IGA nephropathy or IgAN an islet cell transplantation. I’m very encouraged by the progress we have made in each of these areas. In renal transplantation we recently announced the first patient dose in a phase 1b open label study of tegoprubart in Canada, United Kingdom and Australia.